News for Regeneron Pharmaceuticals Stock (REGN)

The Schall Law Firm Declares an Inquiry into Accusations Against Regeneron Pharmaceuticals, Inc. and Advocates for Investors with Losses to Reach Out

Accesswire • 06/04/24

REGN CRUCIAL INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 06/03/24

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 06/02/24

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 06/01/24

ONGOING INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 05/31/24

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewsWire • 05/31/24

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewsWire • 05/31/24

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

GlobeNewsWire • 05/31/24

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

GlobeNewsWire • 05/31/24

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 05/30/24

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

Seeking Alpha • 05/29/24

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

PRNewsWire • 05/29/24

2 Biotech Stocks to Buy in May

The Motley Fool • 05/25/24

Regeneron (REGN) Announces Positive Data on Oncology Candidate

Zacks Investment Research • 05/24/24

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO

GlobeNewsWire • 05/23/24

Mary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering Fair

Business Wire • 05/23/24

3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years

The Motley Fool • 05/23/24

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

GlobeNewsWire • 05/20/24

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

GlobeNewsWire • 05/20/24

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

InvestorPlace • 05/20/24

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 05/19/24

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

GlobeNewsWire • 05/17/24

IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 05/17/24

Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

Business Wire • 05/16/24

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 05/16/24